Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2008

01-04-2008 | Conference Paper

Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging

Authors: Hiroko Tsunoda-Shimizu, Naoki Hayashi, Tsuyoshi Hamaoka, Tomonori Kawasaki, Koichiro Tsugawa, Hiroshi Yagata, Mari Kikuchi, Koyu Suzuki, Seigo Nakamura

Published in: Breast Cancer | Issue 2/2008

Login to get access

Abstract

Background

Neoadjuvant chemotherapy has recently become common therapy for breast cancer. This work studied whether or not the effects of neoadjuvant chemotherapy can be predicted from morphological features of breast cancer in initial diagnostic imaging.

Materials and methods

A total of 186 cases who underwent neoadjuvant chemotherapy at this hospital in 2006 were studied. Morphological features were classified into four categories. One is a type of invasive carcinoma that tends to grow along the mammary ducts (type A1), another is a type of expansively growing invasive carcinoma that is relatively well-defined (type A2), a third is a type of irregularly shaped mass that retracts surrounding tissue (type A3), and the fourth is a mixed type. Thus, the effects of neoadjuvant chemotherapy on carcinomas of the four types were compared on the basis of image and pathological findings. Effects of neoadjuvant chemotherapy were classified into three categories of enlarged mass, pCR, and other, with the latter indicating no change or shrinkage.

Results

Of the 186 total cases, 72 were classified as type A1, 31 as type A2, 52 as type A3, and 31 as a mixed type. Seven of 31 cases of type A2 (22.6%) were cases of an enlarged mass, revealing a high percentage of such cases. Dividing cases into type A2 and other types and looking at the proportion of cases of an enlarged mass thus indicated a significantly higher tendency. pCR was achieved in 6 of 31 cases with type A2 (19.4%). Here, also, the proportion of type A2 cases was significantly higher.

Conclusion

Morphological features prior to neoadjuvant chemotherapy can contribute to determining the effects of the therapy. Expansively growing well-defined masses contain lesions at both extremes, tending to enlarge in some instances or instead allowing pCR, so the course of therapy must be carefully followed when performing neoadjuvant chemotherapy.
Literature
1.
Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006;14:383–9.PubMedCrossRef
2.
Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843–7.PubMedCrossRef
3.
Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ, Ueda S, Yanagisawa T, Sato Y, Tamura S, Noguchi S. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006;12:130–7.PubMedCrossRef
4.
Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:231–8.PubMedCrossRef
5.
Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A. Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer. 2005;12:45–51.PubMedCrossRef
6.
Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, Schubert EK, Livingston RB. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol. 2004;11:1115–24.PubMedCrossRef
7.
Tozaki M, Uno S, Kobayashi T, Aiba K, Yoshida K, Takeyama H, Shioya H, Tabei I, Toriumi Y, Suzuki M, Kawakami M, Fukuda K. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med. 2004;22:246–53.PubMed
8.
Warren RM, Bobrow LG, Earl HM, Britton PD, Gopalan D, Purushotham AD, Wishart GC, Benson JR, Hollingworth W. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;5:1349–60.CrossRef
9.
Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371–9.PubMedCrossRef
10.
Sciuto R, Pasqualoni R, Bergomi S, Petrilli G, Vici P, Belli F, Botti C, Mottolese M, Maini CL. Prognostic value of (99 m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med. 2002;43:745–51.PubMed
11.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMed
12.
Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 2002;94:3107–14.PubMedCrossRef
13.
Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy finding from the national surgical adjuvant breast and bowel project (NSABP) protocol B-18. Cancer. 2002;95:681–95.PubMedCrossRef
14.
Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier M, Dauplat J, Chollet P. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002;20:791–6.PubMed
15.
Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegele P. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001;7:1577–81.PubMed
16.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–69.PubMed
17.
Clahsen PC, Van de Velde CJH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, Van den Broek L, Sahmoud TM, Van de Vijver MJ. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998;16:470–79.PubMed
18.
Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging. 2007;29:615–23.CrossRef
19.
Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006;239:361–74.PubMedCrossRef
20.
Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006;94:427–35.PubMedCrossRef
21.
Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91:1–10.PubMedCrossRef
22.
The Japanese breast cancer society ed. General rule for clinical and pathological studies on breast carcinoma. 15th ed. Kanehara: Tokyo; 2004 (in Japanese).
23.
Maki K, Sakamoto G, Kasumi F. The characteristics of 3 subgroups (papillotubular, solid-tubular, and schirrous) of invasive ductal carcinoma of the breast. Jpn J Breast Cancer. 2006;21:165–69 (in Japanese with English abstract).
24.
Sakamoto G. editors. The breast tumors. Histological typing and clinical behavior. Jiho Tokyo; 2006 (in Japanese).
25.
Horii R, Akiyama F, Ito Y, Matsuura M, Miki Y, Iwase T. Histological features of breast cancer, highly sensitive to chemotherapy. Breast Cancer. 2007;14:393–400.PubMedCrossRef
Metadata
Title
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging
Authors
Hiroko Tsunoda-Shimizu
Naoki Hayashi
Tsuyoshi Hamaoka
Tomonori Kawasaki
Koichiro Tsugawa
Hiroshi Yagata
Mari Kikuchi
Koyu Suzuki
Seigo Nakamura
Publication date
01-04-2008
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-008-0030-7

Other articles of this Issue 2/2008

Breast Cancer 2/2008 Go to the issue

Original Article

Bilateral breast MR imaging: is it superior to conventional methods for the detection of contralateral breast cancer?

Conference Paper

Individualization of breast cancer based on histopathological features and molecular alterations

Conference Paper

Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer

Review Article

Screening and diagnosis of breast cancer in augmented women

Original Article

Screening ultrasonography revealed 15% of mammographically occult breast cancers

Conference Paper

In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits